Key Points
- CFO Eugene Johnston sold 10,000 shares on Dec. 5 at an average price of $1.13 for $11,300, reducing his stake by 7.23% to 128,333 shares (about $145,016).
- Financials are weak: Mangoceuticals reported a ($0.69) EPS with a negative net margin of 4,253.43% and negative ROE of 114.63%, and just $0.08M in quarterly revenue.
- Market and sentiment: MGRX has a $16.97M market cap, trades near its 12‑month low ($0.98) with 50/200‑day SMAs around $1.82/$1.87, and carries an average analyst rating of "Sell".
Mangoceuticals, Inc. (NASDAQ:MGRX - Get Free Report) CFO Eugene Johnston sold 10,000 shares of the firm's stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $1.13, for a total value of $11,300.00. Following the completion of the sale, the chief financial officer directly owned 128,333 shares in the company, valued at approximately $145,016.29. This represents a 7.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Mangoceuticals Stock Performance
NASDAQ MGRX opened at $1.22 on Wednesday. The stock has a 50-day simple moving average of $1.82 and a 200 day simple moving average of $1.87. Mangoceuticals, Inc. has a twelve month low of $0.98 and a twelve month high of $6.15. The stock has a market capitalization of $16.97 million, a PE ratio of -0.34 and a beta of 2.56.
Mangoceuticals (NASDAQ:MGRX - Get Free Report) last released its earnings results on Friday, November 14th. The company reported ($0.69) earnings per share (EPS) for the quarter. Mangoceuticals had a negative net margin of 4,253.43% and a negative return on equity of 114.63%. The business had revenue of $0.08 million during the quarter.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Mangoceuticals stock. Geode Capital Management LLC raised its holdings in Mangoceuticals, Inc. (NASDAQ:MGRX - Free Report) by 35.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 26,498 shares of the company's stock after buying an additional 6,928 shares during the quarter. Geode Capital Management LLC owned 0.51% of Mangoceuticals worth $40,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 56.72% of the company's stock.
Analysts Set New Price Targets
A number of equities analysts recently issued reports on MGRX shares. Wall Street Zen lowered shares of Mangoceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, November 22nd. Weiss Ratings restated a "sell (e+)" rating on shares of Mangoceuticals in a report on Monday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Mangoceuticals currently has an average rating of "Sell".
Get Our Latest Analysis on MGRX
About Mangoceuticals
(
Get Free Report)
Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
